CClinicalTrials.gg
TerminatedNCT05240573SKIUpdated Apr 9, 2026

Strong Kidney Initiative Trial for Dialysis Care Quality

An interventional study of SKI App in Hemodialysis Complication, sponsored by China Medical University Hospital. Terminated at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by China Medical University Hospital · Not applicable, Interventional, and Health services research

Why this study was terminated
The enrollment of study subjects and their compliance with using the APP have been challenging. Due to the funding period having ended, the research team has decided to terminate the study at this stage and conduct a preliminary analysis.
Phase
Not applicable
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Chronic kidney disease (CKD) is an important global health issue that imposes a substantial healthcare burden in both developing and developed economies. The global prevalence of CKD-related mortality was estimated from 9.6 per 100,000 in 1990 to 11.1 per 100,000 in 2010, and the global prevalence of end-stage kidney disease (ESRD) was estimated from 75.9 per 100,000 in 2005 to 100.7 per 100,000 in 2010. In Taiwan, a long-lasting epidemic of CKD has created critical economic and social challenges in its health care system. Over the past 20 years, the annual incidence and prevalence of ESRD in Taiwan have surged from 126 to 361 per million and from 382 to 2,584 per million, respectively. National Health Insurance Bureau in Taiwan has spent a huge budget to support healthcare for ESRD patients requiring maintenance dialysis therapy without observing significant improvement in ESRD prevention and management.

The main challenge in effectively preventing and managing ESRD is to obtain the full-spectrum data, such as lifestyle, diet, over-the-counter medication use, Chinese herbal medication use, and the occurrence of unaware outpatient acute kidney injury, on patients with CKD. This unmeasured information regarding patient's daily life is crucial because patients spend most of their time outside the hospital, even for patients receiving hemodialysis 3-4 times per week spend only 10% of their daily life in the healthcare facility. With the digital transformation of the healthcare system and the blockchain technology brought by the advances in data storage, data transfer, data safety, and computing power, collecting and exchanging comprehensive data becomes possible.

The investigators will establish a full-spectrum kidney database by re-organizing all kidney-related clinical data that were generated in China Medical University Healthcare System (CMUH) and Asia University Healthcare System (AUH), integrating data collected in the dialysis outpatient clinic at CMUH and AUH, such as gait data, grip data, and skin image, combining daily life data such as diet, exercise, and sleeping condition collected from the Strong Kidney Initiative APP (SKI APP) or wearable devices. The investigators will then use the SKI APP and blockchain technology to provide digital service to dialysis patients and to prospectively collect daily life data. The digital service would include the visualization of real-time kidney data, kidney care recommendations, and innovative artificial intelligence-based services for kidney health prediction and suggestion.

This proposed clinical trial aims to evaluate the clinical effectiveness of SKI digital services regarding the outcomes of the rate of emergency department (ED) visits, inpatient admission rate, kidney function improvement, mortality, and healthcare utilization in dialysis patients in 12 months. The clinical trial will be conducted on the patients who regularly receive hemodialysis care from the CMUH and AUH Healthcare Systems. Patients assigned to the intervention arm will be provided the SKI APP and related digital services and patients assigned to the control arm will be provided the ordinary CMUH dialysis care APP. The investigators will provide an education program for the APP and monitor the utilization of APP. The investigators hypothesize that patients receiving the SKI APP will have lower ED and inpatient admission rates, better kidney function maintenance, lower mortality, and decreased healthcare utilization. The results of the SKI trial will provide solid evidence regarding the real-world effectiveness of a comprehensive intelligent kidney care digital service using blockchain technology.

02

Conditions studied

  • Hemodialysis Complication

Keywords

  • Hemodialysis
03

In context

Lead sponsor

China Medical University Hospital is the lead sponsor of 464 studies on the registry; 116 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who receive hemodialysis care at CMUH and AUH Healthcare Systems and agree to participate in this trial.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not receive regular hemodialysis care at CMUH and AUH Healthcare Systems;
  • Patients who do not have a mobile device;
  • Patients who have the capacity/literacy of using an APP;
  • Patients who do not agree to participate.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    SKI App

    Other: SKI App

  • Active comparator
    CMUH Dialysis Care App

    Other: SKI App

Interventions

  • OtherSKI App

    The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion. The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information.

06

What researchers measure

Primary outcomes

  1. Number of emergency department admission

    Admission to emergency department

    Time frame: 12 months after enrollment

  2. Number of hospital admission

    Admission to hospital

    Time frame: 12 months after enrollment

Secondary outcomes

  1. Change in renal function

    Change in eGFR value

    Time frame: 12 months after enrollment

  2. Number of clinical visit

    Clinic visit, hospital length of stay, costs

    Time frame: 12 months after enrollment

  3. Number of hospital days

    Cumulative days of hospital length of stay

    Time frame: 12 months after enrollment

  4. Medical costs

    Cumulative medical costs

    Time frame: 12 months after enrollment

  5. Mortality

    All-cause mortality and cause-specific mortality

    Time frame: 12 months after enrollment

07

Study locations

1 site
  • China Medical University Hospital
    Taichung, Taiwan 404, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05240573
Lead sponsor
China Medical University Hospital
Collaborators
Ministry of Science and Technology, Taiwan
Responsible party
Chin-Chi Kuo (Director of Big Data Center, China Medical University Hospital) — Principal investigator
First posted
Feb 15, 2022
Start date
May 1, 2023
Primary completion
Mar 19, 2024
Completion
Dec 31, 2025
Last update
Apr 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion